Title: Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group
Authors: Aapro, M S ×
van Wijk, F H
van der Burg, M E L
ten Bokkel Huinink, W
Vergote, Ignace
Guastalla, J P
Rosso, R
Kobierska, A
Beex, L V A
Namer, M
Splinter, T E W
Vermorken, J B #
Issue Date: May-2003
Publisher: Pergamon
Series Title: European Journal of Cancer vol:39 issue:8 pages:1141-1143
Abstract: 30 patients with advanced ovarian cancer, all platinum pretreated, were treated with an induction cycle of fotemustine. Maintenance therapy was given to 6 patients. No objective response was observed among the 21 evaluable patients. The main toxicities were gastrointestinal, with grade 3 nausea and vomiting reported in 40% of the patients, and haematological, with grade 4 leucopenia reported in 2 patients and grade 4 thrombocytopenia in 5 patients. Therefore, no role has been demonstrated in our cohort for the use of fotemustine, a nitrosourea, in pretreated ovarian cancer.
ISSN: 0959-8049
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Gynaecological Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science